CLINICAL ASPECTS OF NERVOUS SYSTEM DAMAGE IN NON-HODGKIN’S LYMPHOMAS IN OLDER AGE GROUPS
Abstract
In recent years, there has been a steady increase in the incidence of non-Hodgkin’s lymphomas in the world, especially among patients of older age groups. In most cases, this disease manifests itself as a lesion of the visceral or peripheral lymph nodes, but over the past decades there has been an increase in the number of patients with extranodal non-Hodgkin’s lymphomas, including those with damage to the nervous system. In addition, involvement of neural structures in the pathological process is also possible with systemic lymphoma. Neurological disorders aggravate the condition of this cohort of patients, require timely early diagnosis and risk-adjusted treatment approaches, taking into account the presence of comorbid pathology. This article is devoted to tructuring the knowledge of nervous system lesions in non-Hodgkin’s lymphomas regarding their epidemiology, clinical manifestations, and features therapy in patients of older age groups.
References
Бабичева Л.Г., Байков В.В, Леенман Е.Е. и др. Неходжкинские лимфомы твердой мозговой оболочки. Современная онкология. 2016; 18(2). Доступен по: https://elibrary.ru/item.asp?id = 27720998 (дата обращения 04.05.2023).
Бабичева Л.Г. Экстранодальные неходжкинские лимфомы центральной нервной системы, яичка и поджелудочной железы. Современная Онкология. 2015; 17(5). Доступен по: https://elibrary.ru/item.asp?id = 26099039 (дата обращения 04.05.2023).
Богданов А.Н., Максимов А.Г., Саржевский В.О. и др. Особые формы неходжкинских лимфом. Практическая онкология. 2004; 5(3): 216–22.
Воинов Н.Е., Улитин А.Ю., Читанава Т.В. и др. Первичные лимфомы центральной нервной системы. Вопросы эпидемиологии и лечения. Клинический пример междисциплинарного подхода в терапии. Трансляционная медицина. 2022; 9(1): 49–59. DOI: 10.18705/2311-4495-2022-9-1-49-59.
Губкин А.В., Звонков Е.Е., Кременецкая А.М. и др. Первичные лимфопролиферативные заболевания центральной нервной системы. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2008; 1(4): 323–32. Доступен по: https://www.elibrary.ru/item.asp?id = 11915155 (дата обращения 25.04.2023).
Залуцкий И.В., Науменко Л.В., Возмитель М.В. и др. Сложность диагностики злокачественных внутриглазных лимфом или «маскарадный синдром» в диагностике внутриглазных злокачественных лимфом. Новости хирургии. 2011; 19(1): 122–4. Доступен по: https://www.elibrary.ru/item.asp?id = 17790392 (дата обращения 27.04.2023).
Камолова Ф.Ш., Мудунов А.М., Зейналова П.А. и др. Эпидемиологические и клинические особенности лимфопролиферативных заболеваний с поражением органов головы и шеи. Онкогематология. 2021; 16(3): 105–16. DOI: 10.17650/1818-8346-2021-16-3-105-117.
Комратова К.А., Абугова Ю.Г., Озеров С.С. и др. Первичная диффузная В-крупноклеточная лимфома центральной нервной системы (клинический случай и обзор литературы). Онкогематология. 2017; 12(1): 10–6. DOI: 10.17650/1818-8346-2017-12-1-10-16.
Миненко С.В., Ларина Ю.В., Птушкин В.В. и др. Лечение лимфом центральной нервной системы — обзор литературы и собственные данные. Онкогематология. 2011; 3: 50–7.
Поспелова Т.И., Воропаева Е.Н., Карпова В.С. и др. Поражение центральной нервной системы при диффузной В-клеточной крупноклеточной лимфоме. Journal of Siberian Medical Sciences. 2022; 6(4): 112–32. DOI: 10.31549/2542-1174-2022-6-4-112-132.
Саакян С.В., Амирян А.Г., Андреева Т.А. др. Неходжкинская лимфома (случай сочетанного поражения глаз и орбиты). Вестник офтальмологии. 2015; 131(3): 82–9. Доступен по: https://www.elibrary.ru/item.asp?id = 24067656 (дата обращения 28.04.2023).
Тропинская О.Ф., Серова Н.К., Голанов А.В. и др. Редкий клинический случай витреоретинальной лимфомы. Вестник офтальмологии. 2014; 130(4): 63–7. Доступен по: https://www.elibrary.ru/item.asp?id = 22296321 (дата обращения 28.04.2023).
Тумян Г.С. Вторичное поражение центральной нервной системы при неходжкинских лимфомах. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2010; 3(1): 10–3.
Ahn Y., Ahn H.J., Yoon D.H. et al. Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. Blood Res. 2017; 52(4): 285–92. DOI: 10.5045/br.2017.52.4.285.
Akkas B.E., Vural G.U. The incidence of secondary central nervous system involvement in patients with non-Hodgkin’s lymphoma as detected by 18F-FDG PET/CT. Nucl. Med. Commun. 2013; 34(1): 50–6. DOI: 10.1097/MNM.0b013e32835aaa48.
Baehring J.M., Batchelor T.T. Diagnosis and management of neurolymphomatosis. J. Cancer 2012; 18(5): 463–8. DOI: 10.1097/PPO.0b013e31826c5ad5.
Bai L.Y., Yang M.H., Chiou T.J. et al. Non-Hodgkin lymphoma in elderly patients: experience at Taipei Veterans General Hospital. Cancer. 2003; 98(6): 1188–95. DOI: 10.1002/cncr.11609.
Bataille B., Delwail V., Menet E. et al. Primary intracerebral malignant lymphoma: report of 248 cases. J. Neurosurg. 2000; 92(2): 261–6. DOI: 10.3171/jns.2000.92.2.0261.
Bekar A., Cordan T., Evrensel T. et al. A case of primary spinal intramedullary lymphoma. Surg. Neurol. 2001; 55(5): 261–4. DOI: 10.1016/s0090-3019(01)00405-0.
Beume L.A., Wolf K., Urbach H. et al. Primary intraspinal non-Hodgkin’s lymphoma: case report and review of literature. J. Clin. Neurosci. 2019; 61: 262–4. DOI: 10.1016/j.jocn.2018.11.046.
Bernstein S.H., Unger J.M., Leblanc M. et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516 — the Southwest Oncology Group. J. Clin. Oncol. 2009; 27(1): 114–9. DOI: 10.1200/JCO.2008.16.8021.
Bhardwaj P.V., Abraham A., Alluri S. Primary spinal epidural diffuse large B-cell lymphoma: case report and literature review. Cureus. 2022; 14(9): e28934. DOI: 10.7759/cureus.28934.
Bobillo S., Khwaja J., Ferreri A.J.M. et al. Prevention and management of secondary central nervous system lymphoma. Haematologica. 2023; 108(3): 673–89. DOI: 10.3324/haematol.2022.281457.
Boehme V., Schmitz N., Zeynalova S. et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL). Blood. 2009; 113(17): 3896–3902. DOI: 10.1182/blood-2008-10-182253.
Bourque P.R., Sampaio M.L., Warman-Chardon J. et al. Neurolymphomatosis of the lumbosacral plexus and its branches: case series and literature review. BMC Cancer. 2019; 19(1): 1149. DOI: 10.1186/s12885-019-6365-y.
Bromberg J.E., Doorduijn J.K., Illerhaus G. et al. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation — an International primary central nervous system lymphoma study group project. Haematologica. 2013; 98(5): 808–13. DOI: 10.3324/haematol.2012.070839.
Bromberg J.E.C., Issa S., Bakunina K. et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019; 20(2): 216–28. DOI: 10.1016/S1470-2045(18)30747-2.
Caimi P.F., Barr P.M., Berger N.A. et al. Non-Hodgkin’s lymphoma in the elderly. Drugs Aging. 2010; 27(3): 211–38. DOI: 10.2165/11531550-000000000-00000.
Carnevale J., Rubenstein J.L. The Challenge of primary central nervous system lymphoma. Hematol. Oncol. Clin. North. Am. 2016; 30(6): 1293–1316. DOI: 10.1016/j.hoc.2016.07.013.
Cho H.J., Lee J.B., Hur J.W. et al. A Rare Case of malignant lymphoma occurred at spinal epidural space: a case report. Korean J. Spine. 2015; 12(3): 177–80. DOI: 10.14245/kjs.2015.12.3.177.
Choi Y.J., Shin J.A., Kim Y.H. et al. Neurolymphomatosis of brachial plexus in patients with non-Hodgkin’s lymphoma. Case Rep. Oncol. Med. 2013; 2013: 492329. DOI: 10.1155/2013/492329.
Cingolani A., Gastaldi R., Fassone L. et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin’s lymphomas. J. Clin. Oncol. 2000; 18(19): 3325–30. DOI: 10.1200/JCO.2000.18.19.3325.
Davis J.L. Intraocular lymphoma: a clinical perspective. Eye (Lond). 2013; 27(2): 153–62. DOI: 10.1038/eye.2012.250.
Du P., Chen H., Shen L. et al. Analysis of key factors associated with response to salvage high-dose methotrexate rechallenge in primary central nervous system lymphoma with first relapse. Curr. Oncol. 2022; 29(9): 6642–56. DOI: 10.3390/curroncol29090522.
Eyre T.A., Kirkwood A.A., Wolf J. et al. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. Br. J. Haematol. 2019; 187(2): 185–94. DOI: 10.1111/bjh.16070.
Fratino L., Bernardi D. European experiences on aggressive non-Hodgkin’s lymphoma in elderly patients. Crit. Rev. Oncol. Hematol. 2004; 51(3): 229–40. DOI: 10.1016/j.critrevonc.2004.04.001.
Gliemroth J., Kehler U., Gaebel C. Neuroradiological findings in primary cerebral lymphomas of non-AIDS patients. Clin. Neurol. Neurosurg. 2003; 105(2): 78–86. DOI: 10.1016/s0303-8467(02)00105-1.
Grimm S.A., McCannel C.A., Omuro A.M.P. et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group. Report. Neurology. 2008; 71(17): 1355–60. DOI: 10.1212/01.wnl.0000327672.04729.8c.
Grisariu S., Avni B., Batchelor T.T. et al. Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood. 2010; 115(24): 5005–11. DOI: 10.1182/blood-2009-12-258210.
Grisold W., Grisold A., Marosi C. et al. Neuropathies associated with lymphoma. Neurooncol. Pract. 2015; 2(4): 167–78. DOI: 10.1093/nop/npv025.
Grommes C., DeAngelis L.M. Primary CNS lymphoma. J. Clin. Oncol. 2017; 35(21): 2410–8. DOI: 10.1200/JCO.2017.72.7602.
Grommes C., Rubenstein J.L., DeAngelis L.M. et al. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neur. Oncol. 2019; 21(3): 296–305. DOI: 10.1093/neuonc/noy192.
Haydaroglu Sahin H., Mete A., Pehlivan M. Neurolymphomatosis in non-Hodgkin lymphoma with cranial multineuritis: a case report. Medicine (Baltimore). 2018; 97(15): e0303. DOI: 10.1097/MD.0000000000010303.
Hegde U., Filie A., Little R.F. et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005; 105(2): 496–502. DOI: 10.1182/blood-2004-05-1982.
Hill Q.A., Owen R.G. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev. 2006; 20(6): 319–32. DOI: 10.1016/j.blre.2006.02.001.
Hochberg F.H., Miller D.C. Primary central nervous system lymphoma. J. Neurosurg. 1988; 68(6): 835–53. DOI: 10.3171/jns.1988.68.6.0835.
Iwamoto F.M., DeAngelis L.M., Abrey L.E. Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology. 2006; 66(11): 1763–5. DOI: 10.1212/01.wnl.0000218284.23872.eb.
Kalogeropoulos D., Vartholomatos G., Mitra A. et al. Primary vitreoretinal lymphoma. Saudi J. Ophthalmol. 2019; 33(1): 66–80. DOI: 10.1016/j.sjopt.2018.12.008.
Liu Z., Jiang T., Hou N. et al. Peripheral neurolymphomatosis with tracheal asphyxia: a case report and literature review. BMC Neurol. 2015; 15: 149. DOI: 10.1186/s12883-015-0405-2.
Lynch K.M., Katz J.D., Weinberg D.H. et al. Isolated mononeuropathy multiplex--a rare manifestation of intravascular large B-cell lymphoma. J. Clin. Neuromuscul. Dis. 2012; 14(1): 17–20. DOI: 10.1097/CND.0b013e318262ab5c.
Maartense E., Kluin-Nelemans H.C., Noordijk E.M. Non-Hodgkin’s lymphoma in the elderly. A review with emphasis on elderly patients, geriatric assessment, and future perspectives. Ann. Hematol. 2003; 82(11): 661–70. DOI: 10.1007/s00277-003-0722-1.
Miller D.C., Hochberg F.H., Harris N.L. et al. Pathology with clinical correlations of primary central nervous system non-Hodgkin’s lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer. 1994; 74(4): 1383–97. DOI: 10.1002/1097-0142(19940815)74:4 < 1383::aid cncr2820740432 > 3.0.co;2-1.
Montesinos-Rongen M., Brunn A., Sanchez-Ruiz M. et al. Impact of a faulty germinal center reaction on the pathogenesis of primary diffuse large B cell lymphoma of the central nervous system. Cancers (Basel). 2021; 13(24): 6334. DOI: 10.3390/cancers13246334.
Montesinos-Rongen M., Van Roost D., Schaller C. et al. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood. 2004; 103(5): 1869–75. DOI: 10.1182/blood-2003-05-1465.
Morrison V.A. Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma. Expert Review of Anticancer. Therapy. 2008; 8(10): 1651–8. DOI: 10.1586/14737140.8.10.1651.
Nguyen T.T., Sekiguchi H., Yi E.S. et al. Occult diffuse neoplasm in the lungs: intravascular large B-cell lymphoma. Am. J. Med. 2021; 134(7): 926–9. DOI: 10.1016/j.amjmed.2020.12.028.
Ninan M.J., Morrison V.A. Therapeutic approaches to non-Hodgkin’s lymphoma in the elderly patient. Expert. Rev. Hematol. 2009; 2(2): 173–82. DOI: 10.1586/ehm.09.7.
Ohno H., Maekawa F., Nakagawa M. et al. Two cases of primary diffuse large B-cell lymphoma of the CNS associated with t(8;14)(q24;q32) or t(3;14)(q27;q32) identified by G-banding and fluorescence in situ hybridization applied to metaphase spreads. J. Clin. Exp. Hematop. 2022; 62(4): 242–8. DOI: 10.3960/jslrt.22019.
Peña C., Russo M., Martinez V. et al. Extranodal lymphomas in the public health system in Chile: analysis of 1251 patients from the National Adult Cancer Program. Hematol. Oncol. 2019; 37(1): 47–53. DOI: 10.1002/hon.2547.
Recht L., Mrugala M. Neurologic complications of hematologic neoplasms. Neurol. Clin. 2003; 21(1): 87–105. DOI: 10.1016/s0733-8619(02)00030-0.
Schaff L.R., Grommes C. Primary central nervous system lymphoma. Blood. 2022; 140(9): 971–9. DOI: 10.1182/blood.2020008377.
Talybov R., Beylerli O., Mochalov V. et al. Multiparametric MR imaging features of primary CNS lymphomas. Front. Surg. 2022; 9: 887249. DOI: 10.3389/fsurg.2022.887249.
Taylor J.W., Flanagan E.P., O’Neill B.P. et al. Primary leptomeningeal lymphoma: international primary CNS lymphoma collaborative group report. Neurology. 2013; 81(19): 1690–6. DOI: 10.1212/01.wnl.0000435302.02895.f3.
Terret C., Albrand G., Rainfray M. et al. Impact of comorbidities on the treatment of non-Hodgkin’s lymphoma: a systematic review. Expert. Rev. Hematol. 2015; 8(3): 329–41. DOI: 10.1586/17474086.2015.1024650.
Thiel E., Korfel A., Martus P. et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet. Oncol. 2010; 11(11): 1036–47. DOI: 10.1016/S1470-2045(10)70229-1.
Tomita N., Kodama F., Kanamori H. et al. Secondary central nervous system lymphoma. Int. J. Hematol. 2006; 84(2): 128–35. DOI: 10.1532/IJH97.06091.
Vangeel L., Bleyen J., De Cocker L. Spinal non-Hodgkin lymphoma mimicking epidural hematoma. J. Belg. Soc. Radiol. 2022; 106(1): 132. DOI: 10.5334/jbsr.2928.
Wang Y., Cheung D.S., Chan C.C. Case 01-2017 — Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016. Ann. Eye Sci. 2017; 2: 32. DOI: 10.21037/aes.2017.06.06.
